Managing adverse drug reactions;Umgang mit unerwünschten Arzneimittelwirkungen

Therapeutische Umschau

Volumn 57, Issue 9, 2000, Pages 584-590

  Schlienger, Raymond G ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DIFFERENTIAL DIAGNOSIS; DRUG SURVEILLANCE PROGRAM; DRUG TOXICITY; GERMANY; HUMAN; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DIAGNOSIS, DIFFERENTIAL; DRUG TOXICITY; GERMANY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0346109669     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.57.9.584     Document Type: Article

References (31)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1220-5.
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
3. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307-11.
4. Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158-67.
5. Schlienger RG, Lüscher TF, Schoenenberger RA, Haefeli WE. Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci 1999; 21: 110-5.
6. Johnson JA, Bootman JL. Drug-related morbidiy and mortality. A cost-of-illness model. Arch Intern Med 1995; 155: 1949-56.
7. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-8.
8. Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med 2000; 15: 149-54.
9. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832-40.
10. Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. Br Med J 2000; 320: 1036.
11. Bircher AJ. ed. Arzneimittelallergie und Haut. 1. Auflage. Stuttgart: Georg Thieme Verlag, 1996.
12. Anon. International drug monitoring. The role of the hospital - a WHO report. Drug Intell Clin Pharm 1970; 4: 101-10.
13. Kando J, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. Drugs 1995; 50: 1-6.
14. Krähenbühl-Melcher A, Schlienger R, Krähenbühl S. Unerwünschte Wirkungen von Medikamenten. In: Biollaz J, Dayer P, Galeazzi RL, et al., Hrsg. Grundlagen der Arzneimitteltherapie. 15. Auflage, Basel: Documed AG, 2000 (im Druck).
15. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956-66.
16. Rawlins MD. Adverse reactions to drugs. Br Med J 1981; 282: 974-6.
17. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278: 1895-1906.
18. Coombs RRA, Gell PHG. Classification of allergic reactions responsible for drug hypersensitivity reactions. In: Coombs RRA, Gell PHG, eds. Clinical aspects of immunology. 2nd ed., New York: FA Davis, 1968: 575-96.
19. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
20. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-95.
21. Shear NH. Diagnosing cutaneous adverse reactions to drugs. Arch Dermatol 1990; 126: 94-7.
22. Meyer FP, Tröger U, Röhl FW. Adverse non-drug reactions: An update. Clin Pharmacol Ther 1996; 60: 347-52.
23. Morant J, Ruppanner H, Herausg. Arzneimittel-Kompendium Schweiz. 21. Auflage. Basel: Documed AG, 2000.
24. Dukes MNG, ed. Meyler's side effects of drugs, an encyclopedia of adverse drug reactions and interactions. 13th ed. Amsterdam: Elsevier, 1996.
25. Parfitt K, ed. Martindale, the extra pharmacopoeia. 32nd ed. London: The Pharmaceutical Press, 1999.
26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
27. Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus. A systematic review. Dermatology 2000; 200: 223-31.
28. Guyatt G, Sackett DL, Adachi JD, et al. A clinician's guide for conducting randomized controlled trials in individual patients. Can Med Assoc J 1988; 139: 497-503.
29. Bircher AJ. Stellenwert der In-vivo und In-vitro-Diagnostik bei kutanen Überempfindlichkeitsreaktionen auf Arzneimittel. Schw Ärzteztg 1997; 78: 782-7.
30. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
31. http://www.hin.ch/sanz/